Tuesday, 30 December 2014 21:54

Anticoagulation news items. Week commencing 22nd and 29th December 2014

Biologics license application submitted to FDA for BAX111 for the treatment of Von Willebrand Disease

Biospace Inc.

BAX111 is the first highly-purified recombinant von Willebrand Factor in clinical development, as a treatment option for patients with von Willebrand disease. BAX111 has orphan-drug designation in the EU.


Supplemental New Drug Application submitted to FDA for use of eltrombopag for treatment of chronic ITP in children

Biospace Inc.

The license extension application will be for use in children aged over 6 years who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Currently, eltrombopag is not licensed in any country for treatment of chronic ITP in the paediatric setting.


Duration of Anticoagulation for Venous Thromboembolic Events


This review, based on a case vignette, discusses the evidence for anticoagulant selection and the recommended duration of therapy in patients presenting with venous thromboembolic events



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: